ReviewCurrent rheumatology reports2021
Advances in the Treatment of Behcet's Disease.
Review in Current rheumatology reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06084624 (Evaluation of Topical Rebamipide Versus Topical Betamethasone for Management of Oral Ulcers in Behcet's Disease), which is not on this map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of Topical Rebamipide Versus Topical Betamethasone for Management of Oral Ulcers in Behcet's Disease: A Randomized Clinical Trial
Who cites it
30 citing papers in PubMed, 68 citations in OpenAlex.
- Efficacy and safety of low-dose interleukin 2 for Behçet's syndrome: a randomized, placebo-controlled, double-blind, phase 2 clinical trial.Nature communications · 2026Trial
- Serum DNASE1L3 level as a potential exploratory biomarker for Behçet's disease: a preliminary study.Clinical rheumatology · 2026Article
- Comorbid Inflammatory Diseases in Behçet's Disease: A Multicenter Large Cohort Study.International journal of rheumatic diseases · 2026Observational
- Unraveling the psychological burden of Behçet disease: the impact of anxiety and depression on health-related quality of life outcomes.Orphanet journal of rare diseases · 2026Article
- A Comprehensive Patient-Centric Analysis of Disease Burden, Treatment Challenges, and Unmet Needs in Behçet's Disease: Insights from a Large Cohort Study.Medicina (Kaunas, Lithuania) · 2026Article
- Case Report: From idiopathic recurrent pericarditis to systemic Behçet's Disease: unmasking a unified IL-1-driven autoinflammatory phenotype.Frontiers in immunology · 2026Article
- Evaluation of predictors and clinical outcome after tapering of chronic systemic corticosteroids in Behçet's disease patients.Clinical rheumatology · 2026Observational
- Visual prognosis of Behçet's uveitis patients in China and its associated factors.Frontiers in immunology · 2026Article
- PR3-ANCA Positive Behçet's Disease with Severe Multisystem Involvement: A Diagnostic Challenge.Diagnostics (Basel, Switzerland) · 2025Article
- Molecular and therapeutic effects of mesenchymal stem cell-derived exosomes on autoimmune diseases.World journal of stem cells · 2025Review
- Contemporary and prospective use of azathioprine (AZA) in viral, rheumatic, and dermatological disorders: a review of pharmacogenomic and nanotechnology applications.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Case Report: Exploring the spectrum of A20 haploinsufficiency in children.Frontiers in pediatrics · 2025Article
- Systemic Immunomodulatory Therapy in Uveitis Related to Behçet's Disease: A 10-year Profile.Clinical ophthalmology (Auckland, N.Z.) · 2025Article
- Comparative Study of Adalimumab, Infliximab and Certolizumab Pegol in the Treatment of Cystoid Macular Edema Due to Behçet's Disease.Journal of clinical medicine · 2024Article
- Pulmonary artery involvement in Behçet's disease: A challenging case and comprehensive management approach.Radiology case reports · 2024Article
- Optimizing Behçet Uveitis Management: A Review of Personalized Immunosuppressive Strategies.Medical science monitor : international medical journal of experimental and clinical research · 2024Review
- Article
- Behçet's Disease, Pathogenesis, Clinical Features, and Treatment Approaches: A Comprehensive Review.Medicina (Kaunas, Lithuania) · 2024Review
- Behçet's disease detecting by hemoptysis and recurrent epididymo-orchitis: A case report from Syria.SAGE open medical case reports · 2024Article
- Diagnosing Behçet's disease in the presence of pulmonary artery aneurysm and systemic symptoms: A case report.SAGE open medical case reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewTo assess current management of Behcet's disease (BD). Controversies on therapeutic approaches to different manifestations, whether conventional immunosuppressives (IS) or biologic agents, should be chosen, and options for refractory disease are discussed. RECENT
findingsGlucocorticoids are still the main agents for remission-induction and azathioprine the first-line conventional IS in maintenance phase to prevent relapses of major organ involvement. Apremilast is shown to be a safe and effective option approved by the FDA for oral ulcers. Large case series confirmed the efficacy and safety of TNFα inhibitors and Interferon-α. Promising results are observed with IL-1 inhibitors, ustekinumab, secukinumab, and tocilizumab for refractory BD. Although both conventional IS and biologic agents are effectively used to suppress inflammation in BD, there is still an unmet need for clear therapeutic strategies in the management for different manifestations. Further controlled studies with new biologic agents, anticoagulants and the benefit of concomitant IS usage with biologics are needed to optimize the management of BD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.